Subscribe
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
2021 Year in Review - HER2-Negative Breast Cancer
Olaparib’s OlympiA Trial Crossed the Superiority Limit for Invasive Disease-Free Survival versus Placebo
Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer
Earlier this year, the independent data monitoring committee concluded that the OlympiA trial crossed the superiority boundary for its primary end point of invasive disease-free survival and demonstrated a sustainable, clinically relevant treatment effect for olaparib versus placebo in patients with germline
BRCA
mutation–positive, high-risk,
HER2
-negative, early breast cancer.
Read More ›
Olaparib as Adjuvant Therapy in Patients with BRCA1 or BRCA2 Mutation–Positive Breast Cancer
Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer
A completion of local treatment and neoadjuvant or adjuvant chemotherapy results in significantly longer survival, free of invasive or distant disease than placebo in patients with high-risk,
HER2
-negative early breast cancer, with germline
BRCA1
or
BRCA2
pathogenic variants.
Read More ›
Palbociclib in Combination with Aromatase Inhibitors in Elderly Patients with Estrogen Receptor–Positive and HER2-Negative Advanced Breast Cancer
Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer
Despite their frailty and comorbidities in the elderly patient population, palbociclib was proven to be a well-tolerated treatment in elderly patients with advanced, ER-positive,
HER2
-negative breast cancer.
Read More ›
Dalpiciclib plus Fulvestrant in HR-Positive and HER2-Negative Advanced Breast Cancer
Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer
Dalpiciclib plus fulvestrant has been clinically demonstrated to significantly improve progression-free survival and reduce the risk for disease progression or death.
Read More ›
A Subanalysis of the Phase 3 MONARCH 3 Study of Abemaciclib as Initial Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer
Abemaciclib plus nonsteroidal aromatase inhibitors were shown to be a successful initial treatment in a Japanese subpopulation, with a tolerable safety profile, consistent with findings in the whole population in treating patients with HR-positive,
HER2
-negative advanced breast cancer.
Read More ›
Olaparib Monotherapy in Triple-Negative Breast Cancer
Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer
Olaparib monotherapy has shown promising clinical results in treatment-naïve TNBC with germline or somatic homologous repair deficiency, with fewer adverse events compared with traditional chemotherapy.
Read More ›
Resistance Mechanisms to CDK4/6 Blockade in Advanced HR-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities
Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer
CDK4/6 inhibitors in combination with antiestrogen therapy are the standard of care for HR-positive,
HER2
-negative advanced breast cancer. However, a diverse landscape of resistance to these therapies exists, which has resulted in precision-guided therapeutic strategies that are under active clinical development.
Read More ›
Latest Updates on Targeted Therapy in HR-Positive and HER2-Negative Breast Cancer
Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer
Improved knowledge of the biologic pathways, along with a number of new targeted therapies, has resulted in better outcomes for patients with HR-positive,
HER2
-negative breast cancer. These new therapies have been used in combination with older treatments to optimize patient outcomes.
Read More ›
Advancements in Targeted Therapy and Immunotherapy for Human Breast Cancer
Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer
PARP inhibitors and immune checkpoint inhibitors have changed the breast cancer landscape, with trials that show improved progression-free survival and overall survival.
Read More ›
New Antibody–Drug Conjugates in Breast Cancer
Breast Cancer
2021 Year in Review - HER2-Negative Breast Cancer
Two new antibody–drug conjugates with a topoisomerase I inhibitor payload have recently been added to the therapy options for patients with metastatic TNBC and
HER2
-positive breast cancer.
Read More ›
Page 2 of 3
1
2
3
View the Latest Issue of TON
Read Issue
Home
Issues
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION